<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970462</url>
  </required_header>
  <id_info>
    <org_study_id>2013H0328</org_study_id>
    <nct_id>NCT01970462</nct_id>
  </id_info>
  <brief_title>Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery</brief_title>
  <official_title>Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kathleen Dungan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to determine the safety and efficacy of Sitagliptin in
      patients with stress hyperglycemia or mild diabetes following cardiac surgery. Patients will
      receive Sitagliptin or placebo. Sitagliptin may be of particular use in this patient
      population due to the effects on hepatic glucose production (a major feature of SH), safety
      (lack of contra-indications for heart failure or renal failure and no hypoglycemia), and
      tolerability. The secondary objective of this study is to determine whether the management of
      patients with persistent insulin requirements following cardiac surgery differs among
      patients with stress hyperglycemia or mild diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Fasting Glucose</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in mean fasting glucose at 6 weeks post-discharge.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Self Monitored Blood Glucose</measure>
    <time_frame>2 weeks</time_frame>
    <description>Mean blood glucose at week 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Adherence</measure>
    <time_frame>6 weeks</time_frame>
    <description>adherence defined as 80% of all Sitagliptin doses respectively taken in previous week</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of subjects with glucose &lt;70 mg/dl following time of discharge to 6 weeks.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo prior to discharge and 6 weeks after discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin prior to hospital discharge and 6 weeks following discharge.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Either of the following: Mild Diabetes Mellitus or Stress Hyperglycemia

          -  AND:

          -  Cardiac Surgery

          -  Insulin Requirement between 8-30 units subcutaneous on post-op day 3 or later off
             pressors, off enteral feeding, extubated OR glucose &gt;150 mg/dL at least twice in a 24
             hour period (&gt;4 hours apart) and otherwise not requiring basal insulin

        Exclusion Criteria:

          -  use of pressors, mechanical ventilation, or enteral or parenteral feeding within
             previous 12 hours

          -  glucocorticoids in doses exceeding the equivalent of Prednisone 10 mg/day within the
             previous 48 hours

          -  left ventricular assist device

          -  percutaneous or laparoscopic surgery

          -  end stage renal disease

          -  end stage liver disease

          -  history of pancreatitis

          -  type 1 diabetes

          -  pregnancy

          -  unable to give consent in english

          -  no phone

          -  prisoners

          -  less than 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Dungan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2013</study_first_posted>
  <results_first_submitted>April 14, 2018</results_first_submitted>
  <results_first_submitted_qc>April 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2018</results_first_posted>
  <last_update_submitted>April 14, 2018</last_update_submitted>
  <last_update_submitted_qc>April 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Kathleen Dungan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin</title>
          <description>Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
Sitagliptin: Sitagliptin prior to hospital discharge and 6 weeks following discharge.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients will receive placebo prior to discharge and 6 weeks after discharge.
Placebo: Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Number of patients with at least one dose of study medication</population>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin</title>
          <description>Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
Sitagliptin: Sitagliptin prior to hospital discharge and 6 weeks following discharge.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients will receive placebo prior to discharge and 6 weeks after discharge.
Placebo: Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Fasting Glucose</title>
        <description>Difference in mean fasting glucose at 6 weeks post-discharge.</description>
        <time_frame>6 weeks</time_frame>
        <population>Data not available due to insufficient number of patients to analyze and study stopping early.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
Sitagliptin: Sitagliptin prior to hospital discharge and 6 weeks following discharge.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will receive placebo prior to discharge and 6 weeks after discharge.
Placebo: Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Fasting Glucose</title>
          <description>Difference in mean fasting glucose at 6 weeks post-discharge.</description>
          <population>Data not available due to insufficient number of patients to analyze and study stopping early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Self Monitored Blood Glucose</title>
        <description>Mean blood glucose at week 2</description>
        <time_frame>2 weeks</time_frame>
        <population>Data not available due to insufficient number of patients to analyze and study stopping early.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
Sitagliptin: Sitagliptin prior to hospital discharge and 6 weeks following discharge.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will receive placebo prior to discharge and 6 weeks after discharge.
Placebo: Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively</description>
          </group>
        </group_list>
        <measure>
          <title>Self Monitored Blood Glucose</title>
          <description>Mean blood glucose at week 2</description>
          <population>Data not available due to insufficient number of patients to analyze and study stopping early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adherence</title>
        <description>adherence defined as 80% of all Sitagliptin doses respectively taken in previous week</description>
        <time_frame>6 weeks</time_frame>
        <population>Data not available due to insufficient data and early study termination</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
Sitagliptin: Sitagliptin prior to hospital discharge and 6 weeks following discharge.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will receive placebo prior to discharge and 6 weeks after discharge.
Placebo: Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence</title>
          <description>adherence defined as 80% of all Sitagliptin doses respectively taken in previous week</description>
          <population>Data not available due to insufficient data and early study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hypoglycemia</title>
        <description>Number of subjects with glucose &lt;70 mg/dl following time of discharge to 6 weeks.</description>
        <time_frame>6 weeks</time_frame>
        <population>Data not available due to insufficient number of participants and early study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
Sitagliptin: Sitagliptin prior to hospital discharge and 6 weeks following discharge.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will receive placebo prior to discharge and 6 weeks after discharge.
Placebo: Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia</title>
          <description>Number of subjects with glucose &lt;70 mg/dl following time of discharge to 6 weeks.</description>
          <population>Data not available due to insufficient number of participants and early study closure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin</title>
          <description>Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
Sitagliptin: Sitagliptin prior to hospital discharge and 6 weeks following discharge.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients will receive placebo prior to discharge and 6 weeks after discharge.
Placebo: Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen Dungan</name_or_title>
      <organization>Ohio State University</organization>
      <phone>614-685-3333</phone>
      <email>kathleen.dungan@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

